# Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL

> **NCT07389356** · NA · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 70 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide
- **DRUG:** Rituximab+Gemcitabine+Oxaliplatin

## Key facts

- **NCT ID:** NCT07389356
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-25
- **Primary completion:** 2027-10-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07389356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07389356, "Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07389356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*